Skip to main content

Know the Signs of Glanzmann's Thrombasthenia.

Glanzmann's thrombasthenia (GT) is a rare bleeding disorder that requires careful diagnosis.1 For a clinical resource on a diagnostic algorithm for GT, reach out to your Novo Nordisk Representative.

Diagnosing Glanzmann’s thrombasthenia can be difficult.

The diagnosis of Glanzmann’s thrombasthenia is often missed because it shares symptoms with other acquired platelet disorders and von Willebrand disease.1,2

Common symptoms for Glanzmann’s thrombasthenia include:3

Nosebleeds (epistaxis)


Heavy menstrual bleeding


Gingival bleeding


Easy bruising, purpura, and petechiae


Subcutaneous hematomas


Dental bleeding


Gastrointestinal bleeding

How do GT patients usually present?

2.5 year-old patient presented to emergency department with >1-hour episode of severe epistaxis and history of recurrent epistaxis (~2-3 bleeding episodes per month).4,a

14 year-old patient presented with heavy menstrual bleeding requiring 10 tampons per day. The patient had a history of gingival bleeding and epistaxis and was diagnosed with GT at 8 years old.5,a

18 year-old patient presented with an average hemoglobin of 3.6 g/dL over the past 6 months from chronic gingival bleeding alone. The patient was diagnosed at 2 years old and has a history of chronic gingivitis and associated gum bleeds since early childhood.6,a

aThese are actual patient cases.

See a diagnostic algorithm for Glanzmann’s thrombasthenia.

It is important to include GT in the differential diagnosis.1 Reach out to your local Novo Nordisk Representative to walk through our digital algorithm and treatment considerations.

Enter your zip code to find your rep.

Vial options

How to administer

NovoSeven® RT


coagulation disorders code icon

Quick reference to GT dosing

in surgery.


Child standing

Hear from real patients living

with GT.

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information including boxed Warning.

References

  1. Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 2015;6:219-227.
  2. Lambert MP. What to do when you suspect an inherited platelet disorder. Hematology Am Soc Hematol Educ Program. 2011;2011:377-383.
  3. Poon MC, Di Minno G, d’Oiron R, et al. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92-99.
  4. Recht M, Chitlur M, Lam D, et al. Epistaxis as a common presenting symptom of Glanzmann’s thrombasthenia, a rare qualitative platelet disorder: illustrative case examples. Case Rep Emerg Med. 2017:8796425.
  5. Lu M, Yang X. Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann’s thrombasthenia: illustrated case studies. BMC Womens Health. 2018;18(1):45.
  6. Ghosh A, Kumar S, Chacko R, et al. Total extraction as a treatment for anaemia in a patient of Glanzmann’s thrombasthenia with chronic gingival bleed: case report. J Clin Diagn Res. 2016;10(1):ZD11-ZD12.